Dr. Christopher Paul Filson, MD, MS

Dr. Filson practices at Southern California Permanente Medical Group in Los Angeles, California.

Dr. Filson's NPI, 1437275385, was assigned on March 22, 2007. Dr. Filson graduated from University Of Michigan Medical School in 2006. Dr. Filson's Georgia license number on file is 073548.

Dr. Filson's primary practice is Southern California Permanente Medical Group, at 4760 W Sunset Blvd, Los Angeles, CA 90027 in Los Angeles County. The practice phone is (323) 783-4011.

Dr. Filson's primary practice is Southern California Permanente Medical Group in Los Angeles, California. Dr. Filson is also affiliated with Kaiser Permanente Los Angeles Medical Center. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Filson to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Filson practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Filson's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Filson is board certified in urology by the American Board of Urology. Dmand AI has Dr. Filson's licenses on file in 3 states: Georgia, California and Michigan.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, prostate cancer, prostate surgery, testicular dysfunction, transurethral procedures and urinary endoscopy among the conditions Dr. Filson treats.

CMS data shows 147 Medicare services from Dr. Filson across 6 procedure codes in 2023, for 11 Medicare patients. Medicare paid $9,635 for them.

CMS counts 11 Medicare patients who saw Dr. Filson in 2024. The largest group is 85 and over, with 0 patients. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Filson's median patient age at 69, with 9% women.

In 2024, Dr. Filson wrote 861 Medicare Part D claims for 292 patients. 86% of them were for generic drugs. CMS names the drug for 787 of them, across 12 drugs with 11 or more claims each, at $93,296 in total drug cost. In 2023, CMS named 132 claims across 4 drugs.

Dr. Filson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Filson as offering telehealth.

Dmand AI links 94 papers to Dr. Filson, published from 2010 to 2025. 2019 was the busiest year, with 12. The most frequent topics are Prostatic Neoplasms, Medicare and Prostate. Dr. Filson has published most often in Urology. Dr. Filson's most frequent co-authors are Mehrdad E. Alemozaffar, James D. Brooks, MD and Peter R. Carroll, MD.

CMS Open Payments shows 3 general payments to Dr. Filson from 3 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 97% of the total. Elekta, Inc. paid the most, $124. It also lists 2 research payments totaling $1,560 from 2020 to 2021.

Dmand AI lists 2 awards for Dr. Filson, most recently Member in 2023.

Dr. Filson graduated from University Of Michigan Medical School in 2006. Dr. Filson is a member of AOA, ASCO, AUA and Society of Urologic Oncology.

Dr. Filson is in network with 8 carriers, including Aetna, Cigna and Kaiser Permanente. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.